Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients: A Retrospective Cohort Study

Jeffrey M. Tessier, Thaddeus Puzio, Andrew Young, Luke Wolfe, Jinfeng Han, Therese M. Duane

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Linezolid is associated infrequently with bone marrow suppression in immunocompetent patients, but hematologic complications from linezolid in transplant recipients are understudied. This study evaluated the hematologic safety of linezolid in solid organ transplant recipients. Methods: We performed a retrospective study of inpatients at our institution treated with linezolid from June 1, 2009 until June 6, 2012. The solid organ transplant cohort (TP) was compared with the non-transplant cohort (NTP) using parameters related to linezolid safety. Outcomes included incidences of leukopenia or thrombocytopenia at the end of linezolid treatment (EOT), lengths of stay, and blood product requirements. Results: The TP cohort included 110 patients; the NTP cohort included 583 patients. Baseline parameters were similar between the TP and NTP cohorts. Non-transplant patients were more likely to have methicillin-resistant Staphylococcus aureus (MRSA), whereas TP patients received more doses of linezolid (17.0 vs. 11.3, p<0.001) and were more likely to receive other drugs associated with thrombocytopenia (91.7% vs. 11.3%, p<0.0001). Transplant patients with normal platelet counts at baseline were more likely to have EOT thrombocytopenia (29.3% vs. 10.7%, p=0.005), and multivariable regression analysis confirmed only a beginning platelet count less than 150,000 platelets per micoliter to be significantly different between groups: 43% TP versus 26.9% NTP (p=0.0009) making it the only independent predictor of EOT thrombocytopenia. Finally, TP patients were more likely to require platelet transfusions compared with the NTP cohort. Conclusions: Transplant patients who received linezolid had a higher incidence of EOT thrombocytopenia and platelet transfusions, compared with NTP. Transplant patients who are thrombocytopenic at baseline are at the greatest risk. These findings may relate to more frequent use of drugs associated with marrow suppression or greater linezolid exposure in the TP cohort. Clinicians caring for transplant patients should take into account this higher risk of thrombocytopenia and need for platelets when considering use of linezolid in this population.

Original languageEnglish (US)
Pages (from-to)361-367
Number of pages7
JournalSurgical Infections
Volume16
Issue number4
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Linezolid
Thrombocytopenia
Cohort Studies
Retrospective Studies
Transplants
Therapeutics
Platelet Transfusion
Platelet Count
Transplant Recipients

ASJC Scopus subject areas

  • Surgery
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients : A Retrospective Cohort Study. / Tessier, Jeffrey M.; Puzio, Thaddeus; Young, Andrew; Wolfe, Luke; Han, Jinfeng; Duane, Therese M.

In: Surgical Infections, Vol. 16, No. 4, 01.08.2015, p. 361-367.

Research output: Contribution to journalArticle

Tessier, Jeffrey M. ; Puzio, Thaddeus ; Young, Andrew ; Wolfe, Luke ; Han, Jinfeng ; Duane, Therese M. / Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients : A Retrospective Cohort Study. In: Surgical Infections. 2015 ; Vol. 16, No. 4. pp. 361-367.
@article{6ee4beec6a7240b7844e4b1383fcbad3,
title = "Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients: A Retrospective Cohort Study",
abstract = "Background: Linezolid is associated infrequently with bone marrow suppression in immunocompetent patients, but hematologic complications from linezolid in transplant recipients are understudied. This study evaluated the hematologic safety of linezolid in solid organ transplant recipients. Methods: We performed a retrospective study of inpatients at our institution treated with linezolid from June 1, 2009 until June 6, 2012. The solid organ transplant cohort (TP) was compared with the non-transplant cohort (NTP) using parameters related to linezolid safety. Outcomes included incidences of leukopenia or thrombocytopenia at the end of linezolid treatment (EOT), lengths of stay, and blood product requirements. Results: The TP cohort included 110 patients; the NTP cohort included 583 patients. Baseline parameters were similar between the TP and NTP cohorts. Non-transplant patients were more likely to have methicillin-resistant Staphylococcus aureus (MRSA), whereas TP patients received more doses of linezolid (17.0 vs. 11.3, p<0.001) and were more likely to receive other drugs associated with thrombocytopenia (91.7{\%} vs. 11.3{\%}, p<0.0001). Transplant patients with normal platelet counts at baseline were more likely to have EOT thrombocytopenia (29.3{\%} vs. 10.7{\%}, p=0.005), and multivariable regression analysis confirmed only a beginning platelet count less than 150,000 platelets per micoliter to be significantly different between groups: 43{\%} TP versus 26.9{\%} NTP (p=0.0009) making it the only independent predictor of EOT thrombocytopenia. Finally, TP patients were more likely to require platelet transfusions compared with the NTP cohort. Conclusions: Transplant patients who received linezolid had a higher incidence of EOT thrombocytopenia and platelet transfusions, compared with NTP. Transplant patients who are thrombocytopenic at baseline are at the greatest risk. These findings may relate to more frequent use of drugs associated with marrow suppression or greater linezolid exposure in the TP cohort. Clinicians caring for transplant patients should take into account this higher risk of thrombocytopenia and need for platelets when considering use of linezolid in this population.",
author = "Tessier, {Jeffrey M.} and Thaddeus Puzio and Andrew Young and Luke Wolfe and Jinfeng Han and Duane, {Therese M.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1089/sur.2013.190",
language = "English (US)",
volume = "16",
pages = "361--367",
journal = "Surgical Infections",
issn = "1096-2964",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Thrombocytopenia Associated with Linezolid Therapy in Solid Organ Transplant Recipients

T2 - A Retrospective Cohort Study

AU - Tessier, Jeffrey M.

AU - Puzio, Thaddeus

AU - Young, Andrew

AU - Wolfe, Luke

AU - Han, Jinfeng

AU - Duane, Therese M.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: Linezolid is associated infrequently with bone marrow suppression in immunocompetent patients, but hematologic complications from linezolid in transplant recipients are understudied. This study evaluated the hematologic safety of linezolid in solid organ transplant recipients. Methods: We performed a retrospective study of inpatients at our institution treated with linezolid from June 1, 2009 until June 6, 2012. The solid organ transplant cohort (TP) was compared with the non-transplant cohort (NTP) using parameters related to linezolid safety. Outcomes included incidences of leukopenia or thrombocytopenia at the end of linezolid treatment (EOT), lengths of stay, and blood product requirements. Results: The TP cohort included 110 patients; the NTP cohort included 583 patients. Baseline parameters were similar between the TP and NTP cohorts. Non-transplant patients were more likely to have methicillin-resistant Staphylococcus aureus (MRSA), whereas TP patients received more doses of linezolid (17.0 vs. 11.3, p<0.001) and were more likely to receive other drugs associated with thrombocytopenia (91.7% vs. 11.3%, p<0.0001). Transplant patients with normal platelet counts at baseline were more likely to have EOT thrombocytopenia (29.3% vs. 10.7%, p=0.005), and multivariable regression analysis confirmed only a beginning platelet count less than 150,000 platelets per micoliter to be significantly different between groups: 43% TP versus 26.9% NTP (p=0.0009) making it the only independent predictor of EOT thrombocytopenia. Finally, TP patients were more likely to require platelet transfusions compared with the NTP cohort. Conclusions: Transplant patients who received linezolid had a higher incidence of EOT thrombocytopenia and platelet transfusions, compared with NTP. Transplant patients who are thrombocytopenic at baseline are at the greatest risk. These findings may relate to more frequent use of drugs associated with marrow suppression or greater linezolid exposure in the TP cohort. Clinicians caring for transplant patients should take into account this higher risk of thrombocytopenia and need for platelets when considering use of linezolid in this population.

AB - Background: Linezolid is associated infrequently with bone marrow suppression in immunocompetent patients, but hematologic complications from linezolid in transplant recipients are understudied. This study evaluated the hematologic safety of linezolid in solid organ transplant recipients. Methods: We performed a retrospective study of inpatients at our institution treated with linezolid from June 1, 2009 until June 6, 2012. The solid organ transplant cohort (TP) was compared with the non-transplant cohort (NTP) using parameters related to linezolid safety. Outcomes included incidences of leukopenia or thrombocytopenia at the end of linezolid treatment (EOT), lengths of stay, and blood product requirements. Results: The TP cohort included 110 patients; the NTP cohort included 583 patients. Baseline parameters were similar between the TP and NTP cohorts. Non-transplant patients were more likely to have methicillin-resistant Staphylococcus aureus (MRSA), whereas TP patients received more doses of linezolid (17.0 vs. 11.3, p<0.001) and were more likely to receive other drugs associated with thrombocytopenia (91.7% vs. 11.3%, p<0.0001). Transplant patients with normal platelet counts at baseline were more likely to have EOT thrombocytopenia (29.3% vs. 10.7%, p=0.005), and multivariable regression analysis confirmed only a beginning platelet count less than 150,000 platelets per micoliter to be significantly different between groups: 43% TP versus 26.9% NTP (p=0.0009) making it the only independent predictor of EOT thrombocytopenia. Finally, TP patients were more likely to require platelet transfusions compared with the NTP cohort. Conclusions: Transplant patients who received linezolid had a higher incidence of EOT thrombocytopenia and platelet transfusions, compared with NTP. Transplant patients who are thrombocytopenic at baseline are at the greatest risk. These findings may relate to more frequent use of drugs associated with marrow suppression or greater linezolid exposure in the TP cohort. Clinicians caring for transplant patients should take into account this higher risk of thrombocytopenia and need for platelets when considering use of linezolid in this population.

UR - http://www.scopus.com/inward/record.url?scp=84937951982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937951982&partnerID=8YFLogxK

U2 - 10.1089/sur.2013.190

DO - 10.1089/sur.2013.190

M3 - Article

C2 - 26207396

AN - SCOPUS:84937951982

VL - 16

SP - 361

EP - 367

JO - Surgical Infections

JF - Surgical Infections

SN - 1096-2964

IS - 4

ER -